Table 3 Safety population and extent of exposure
From: Safety and pharmacokinetics of a highly bioavailable resveratrol preparation (JOTROL TM)
Part 1 | Part 2 | Overall | |||
|---|---|---|---|---|---|
Treatment A | Treatment B | Treatment C | Treatment D | ||
Number of subjects who received at least one dose, N | 21 | 16 | 18 | 15 | 24 |
Female | 14 (66.7) | 10 (62.5) | 10 (55.6) | 8 (53.3) | 14 (58.3) |
Male | 7 (33.3) | 6 (37.5) | 8 (44.4) | 7 (46.7) | 10 (41.7) |
Number of subjects who completed each treatment period, n (%) | 16 (76.2%) | 15 (93.8%) | 15 (83.3%) | 14 (93.3%) | – |
Number of subjects who completed all treatment periods (ABCD), n (%) | – | – | – | – | 11 (45.8%) |
Number of subjects who completed all part 1 treatment periods (ABC), n (%) | – | – | – | – | 15 (62.5%) |
Number of subjects who completed at least one treatment period, n (%) | – | – | – | – | 24 (100%) |